

MAY 2020

Update Notes

Update Summary		
New Test Activation	5/26/2020	FRDIG - "Digoxin, Free, Serum"
New Test Activation	5/26/2020	HEPCR - "Hepatitis E Virus by Quantitative PCR"
New Website Listing	5/18/2020	INT1G - "Interleukin 1 beta"
New Website Listing	4/22/2020	INTBG - "Interferon-Beta IgG, MAID"
Update Existing Test	5/18/2020	BARGM - "Bartonella quintana IgG IgM Ab"
Update Existing Test	5/18/2020	COCID - "Coccidioides Ab (ID)"
Update Existing Test	4/22/2020	COVWD - "SARS-CoV-2 Qualitative"
Update Existing Test	5/18/2020	DHEA - "DHEA (Dehydroepiandrosterone), Unconjugated,
		LC/MS/MS"
Update Existing Test	5/18/2020	<u>DIGI - "Digitoxin"</u>
Update Existing Test	5/18/2020	FROC - "Fluoroquinolone-Resistant Organism, Culture"
Update Existing Test	5/18/2020	INT2R - "Interleukin-2 Receptor, Soluble, Serum"
Update Existing Test	5/18/2020	INT6 - "Interleukin 6, Serum"
Update Existing Test	5/18/2020	INTL8 - "Interleukin 8, Serum"
Update Existing Test	5/18/2020	PRINS - "Proinsulin, Intact"
Update Existing Test	5/4/2020	THIOS - "Thiopental and Metabolite Serum/Plasma"
Update Existing Test	5/18/2020	TNFA - "Tumor Necrosis Factor - Alpha, Serum"
Inactivate Test With Replacement	5/26/2020	APOEG - "Apo E Genotype for Alzheimer" replaced by APOE -
		<u>"Admark® ApoE Genotype Analysis and Interpretation (Sympto)</u>
Inactivate Test With Replacement	5/4/2020	COV19 - "SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR" replaced
		by COVLR - "SARS-CoV-2 RNA (COVID-19), Qualitative NAAT"
Inactivate Test With Replacement	5/18/2020	PETH - "Phosphatidylethanol (PEth)" replaced by PETHB -
		"Phosphatidylethanol (PEth), Whole Blood"
Inactivate Test Without Replacement	4/17/2020	<u>RC209 - "Chymopapain IgE"</u>



New Test Activation					
Effective Date	5/26/2020				
Name	Digoxin, Free, Serum				
Code	FRDIG				
CPT Code(s)	80163				
Notes	Do not take biotin or any supplements containing biotin for 12 hours prior to testing.				
Specimen Requirements					
Specimen Required	Draw blood in a SST, 6-8 hours after last digoxin dose. Centrifuge within 2 hours of collection, remove serum from cells and send 1.0 mL serum (0.5 mL minimum) refrigerated in a screw-capped plastic vial.				
Alternate Specimen	Serum: Red-top				
Stability	Room temperature: Unacceptable; Refrigerated: 7 days; Frozen: 180 days				
Performing Information					
Methodology	Ultrafiltration followed by Electrochemiluminescent Immunoassay				
Reference Range	≥ 16 years 0.4 - 0.9 ng/mL Toxic Concentration ≥3.0 ng/mL				
Performed Days	Monday - Sunday				
Turnaround Time	2 - 3 days				
Performing Laboratory	Mayo Medical Laboratories				
Interface Information					
Legacy Code ¹	FRDIG				
Interface Order Code	3800080				
Result Code	Name LOINC Code AOE/Prompt ²				
3800080	Digoxin, Free, S 3562-6 No				



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

	Referral T	•			
	Collect	ed: 04/22/2020	0 17:13	Received: 04/22/2020	17:13
Test Name	Result	Flag	Ref-Ranges	<u>Units</u>	<u>Site</u>
Digoxin, Free, Serum	0.4		0.4-0.9	ng/mL	MMRL
>=3.0 ng/mL(Toxic conce	entration)				
ADDITIONAL INFORMATION This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.					
Test Performed by: Mayo Clinic Laboratorie 200 First Street SW, Ro Lab Director: William (ochester, MN 55905	-	404292		
	М	IMRL: MAYO MEDICA	L REFERENCE LA	<u>Perforr</u> B 3050 Superior Drive NW Rochester N	<u>ning Site:</u> IN 55901



New Test Activation				
Effective Date	5/26/2020			
Name	Hepatitis E Virus by Quantitative PCR			
Code		HEPCR		
CPT Code(s)	87799			
Notes				
Specimen Requirements				
Specimen Required	— ·	Draw blood in a SST. Centrifuge, remove serum from cells and send 1.0 mL serum (0.5 mL minimum) frozen in a screw-capped plasic vial.		
Alternate Specimen	Plasma: Lavender EDTA			
Rejection Criteria	Heparinized specimens			
Stability	Room temperature: 24 hours; Refrigerated: 1 week; Frozen: 1 week			
Performing Information				
Methodology	Qualitative Polymerase Chain Reaction			
Reference Range	Not detected			
Performed Days	Monday, Thursday			
Turnaround Time	3 - 6 days			
Performing Laboratory	ARUP R	eference Laborator	у	
Interface Information				
Legacy Code ¹	HEPCR			
Interface Order Code		3600154		
Result Code	Name	LOINC Code	AOE/Prompt ²	
3600155	Hepatitis E Quant by PCR, Source <i>Acceptable Prompt Responses:</i> Serum Plasma	31208-2	Yes	
3600156	Hepatitis E Quant by PCR, IU/mL	69961-1	No	
3600157	Hepatitis E Quant by PCR, Log IU/mL	78750-7	No	
	Hepatitis E Quant by PCR, Interp	48767-8	No	



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

	Referral Testi	ng				
	Collected: 04	/22/2020) 17:22	Received	04/22/2020	17:22
Test Name	<u>Result</u>	<u>Flag</u>	Ref-Ranges	<u>8</u>	<u>Units</u>	<u>Site</u>
Hepatitis E Virus by Quantitative PCR	R					
Hepatitis E Quant by PCR, Source	Plasma					ARRL
Hepatitis E Quant by PCR, IU/mL	<1,800				IU/mL	ARRL
Hepatitis E Quant by PCR, Log IU/mL	< 3.3				log IU/mL	ARRL
Hepatitis E Quant by PCR, Interp	Not Detected		Not Detecte	ed		ARRL
INTERPRETIVE INFORMATION: Hepa PCR The quantitative range of this (1,800- 180,000,000 IU/mL). On approximately 2.25 copies/mL. A negative result (less than 3 1,800 IU/mL) does not rule out inhibitors in the patient spect concentrations below the level Inhibition may also lead to un quantitation. Test developed and characteris Laboratories. See Compliance S: Performed By: ARUP Laboratorie. 500 Chipeta Way	titis E Virus by Qu assay is 3.3-8.3 e IU/mL of HEV RNA .3 log IU/mL or le the presence of PG imen or HEV RNA of detection of th derestimation of v: tics determined by tatement B: arupla	3 log : is cs that cR ne test iral ARUP	IU/mL an z.			
Salt Lake City, UT 84108 Laboratory Director: Julio C. 1	Delgado, MD, MS					
					Perfor	ming Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



New Website Listing					
Effective Date	5/18/2020				
Name	Interleukin 1 beta				
Code		INT1G			
CPT Code(s)	83520				
Notes					
Specimen Requirements					
Specimen Required		Draw blood in a SST. Centrifuge, remove serum from cells within 2 hours of collection and send 1.0 mL serum (0.4 mL) frozen in a screw-capped plastic vial. CRITICAL FROZEN.			
Alternate Specimen	Serum: Plain red	Serum: Plain red			
Rejection Criteria	Refrigerated specimens, heat-inactivated specimens				
Stability	Room temperature: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year				
Performing Information					
Methodology	Quantitative I	Multiplex Bead As	ssay		
Reference Range	 ≤ 6.7 pg/mL Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day. 				
Performed Days	Sunday-Saturday				
Turnaround Time	2-5 days				
Performing Laboratory	ARUP Reference Laboratory				
Interface Information					
Legacy Code ¹		INT1G			
Interface Order Code		3503990			
Result Code	Name	LOINC Code	AOE/Prompt ²		
3503990	Interleukin 1 beta	13629-1	No		



EXAMPLE, REPORT WX0000073111 F 02/15/1985 35 Y

	Referral Te		aived. 04/22/2020	47.04
	Collecte	d: 04/22/2020 17:34 Rec	eived: 04/22/2020	17:34
Test Name	<u>Result</u>	Flag Ref-Ranges	<u>Units</u>	<u>Site</u>
Interleukin 1 beta	<5	<=36	pg/mL	ARRL
INTERPRETIVE INFORMATION: Cytokines Results are used to understand the pathophysiology of immune, infectious, or inflammatory disorders, or may be used for research purposes. Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS				mina Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



New Website Listing						
Effective Date	4/22/2020					
Name	Interferon-Beta IgG, MAID w/reflex to Neutralization					
Code		INTBG				
CPT Code(s)	83516 If Interferon - beta igG is positive, Nab an additional charge (86382)	83516 If Interferon - beta igG is positive, Nab Feron® Neutralizing Antibody Test will be added at an additional charge (86382)				
Notes	Collect at least 8 hou	rs after interfero	n injection.			
Specimen Requirements	;					
Specimen Required	Draw blood in a SST. Centrifuge, remove serur minimum) refrigerated in a screw-capped plas		send 1.5 mL serum (0.5 mL			
Alternate Specimen	Serum: Red-top					
Stability	Room temperature: 7 days; Refrigerated: 14 days; Frozen: 30 days					
Performing Information						
Methodology	Multi-Analyte Im	munodetection (MAID)			
Reference Range	Ν	legative				
Performed Days	Tuesday					
Turnaround Time	3-10 days					
Performing Laboratory	Quest Infectious Disease					
Interface Information						
Legacy Code ¹		NTFBAB				
Interface Order Code	3	512660				
Result Code	Name	LOINC Code	AOE/Prompt ²			
3512660	Interferon-Beta IgG, MAID w/reflex to Neutralization	27871-3	No			



EXAMPLE, REPORT WX0000073111 F 02/15/1985 35 Y

	Referral Test	ina				
		•	0 18:11	Received:	04/22/2020	18:11
Test Name	<u>Result</u>	Flag	Ref-Range	<u>s L</u>	<u> Inits</u>	<u>Site</u>
Interferon-Beta IgG, MAID	See Below					WMFD
Test INTERFERON-BETA IGG, M INTERFERON-BETA USED FOR TREATMENT INTERFERON-BETA IGG:	Result Flag Ref Ra AID (REFLEX TO NEUTRALIZA BASELINE <1.6 <4.0 u	TION)				
	units IgG not detected units IgG detected					
Some multiple sclerosis patients receiving recombinant interferon-beta (IFNb) develop IFNb-specific antibodies that may block the therapeutic effect of the treatment. This assay screens for IgG antibodies capable of binding to IFNb; all samples with detectable IFNb binding antibodies are then tested for IFNb neutralizing antibodies using a bioassay. Approximately two weeks are required to perform the neutralization bioassay; those results will be reported separately when available.						
characteristics have b Infectious Disease. It FDA. This assay has be	d and its analytical perf een determined by Quest I has not been cleared or en validated pursuant to d for clinical purposes.	iagnost approve	ics ed by			
33608 Ortega Highway,	gnostics Infectious Disea San Juan Capistrano, CA 9 , Director, CLIA 05D06442	2675,			Perforr	ning Site:

WMFD: FOCUS DIAGNOSTICS, INC. (QUEST DIAGNOSTICS) 11331 Valley View Street Cypress CA 906304717



Update Existing Test					
Effective Date	5/18/2020				
Name	Bartonella quintana IgG IgM Ab				
Code	BARGM				
Interface Order Code	3704920				
Legacy Code	BARTSP				
Notes	Minimum volume change				
Required Testing Changes					
Specimen Required	Draw blood in a SST. Centrifuge, separate serum from cells within 2 hours of collection and send 1.0 mL serum (0.3 mL minimum) refrigerated in a screw-capped plastic vial.				

Update Existing Test	
Effective Date	5/18/2020
Name	Coccidioides Ab (ID)
Code	COCID
Interface Order Code	3680490
Legacy Code	COCABIDARP
Notes	Requested volume change
Required Testing Change	25
Specimen Required	Draw blood in a SST. Centrifuge, separate and send 0.5 mL serum (0.3 mL minimum) refrigerated in a screw-capped plastic vial.

Update Existing Test	Update Existing Test				
Effective Date	4/22/2020				
Name	SARS-CoV-2 Qualitative				
Code	COVWD				
Interface Order Code	3000065				
Legacy Code	COVWD				
Notes	CPT change				
Required Testing Change	25				
CPT Code(s)	87635 (U0003)				



Update Existing Test	
Effective Date	5/18/2020
Name	DHEA (Dehydroepiandrosterone), Unconjugated, LC/MS/MS
Code	DHEA
Interface Order Code	3700510
Legacy Code	DHEA
Notes	Alternate specimen change
Required Testing Change	25
Specimen Required	Draw blood in a plain-red top tube. Centrifuge, separate serum from cells and send 0.5 mL serum (0.3 mL minimum) refrigerated in a screw-capped plastic vial. Overnight fasting is preferred
Alternate Specimen	No other acceptable specimens.
Rejection Criteria	SST

Update Existing Test				
Effective Date	5/18/2020			
Name	Digitoxin			
Code	DIGI			
Interface Order Code	3	683100		
Legacy Code	Ľ	DIGIARP		
Notes	Stability, Performed days, Reference Range, T change.	urnaround Time,	CPT4 Code changes and name	
Required Testing Change	es			
Name	Digitoxin Quantitative, Serum or Plasma			
CPT Code(s)	30375 (G0480)			
Stability	Room temperature: Undetermined ; Refrigera	ted: 1 week ; Froz	zen: 3 months	
Methodology	Quantitati	ve Immunoassay	1	
Reference Range	Se	e report		
Performed Days	Varies			
Turnaround Time	6-9 days			
Result Code	Name	LOINC Code	AOE/Prompt ²	
3683100	Digitoxin Quantitative, Serum or Plasma	3559-2	No	



Update Existing Test	
Effective Date	5/18/2020
Name	Fluoroquinolone-Resistant Organism, Culture
Code	FROC
Interface Order Code	3623200
Legacy Code	FROC
Notes	Performed days comment added
Required Testing Change	es
	Sunday-Saturday
Performed Days	Negative reported at 4 days;
	Positives as soon as detected

Update Existing Test	
Effective Date	5/18/2020
Name	Interleukin-2 Receptor (CD25), Soluble
Code	INT2R
Interface Order Code	3504010
Legacy Code	INT2R
Notes	Test name, minimum volume, reference range, alternate specimen, and performed days changes.
Required Testing Change	25
Name	Interleukin-2 Receptor, Soluble, Serum
Specimen Required	Draw blood in a SST. Centrifuge, remove serum from cells within 2 hours and send 1.0 mL serum (0.4 mL minimum) frozen in a screw-capped plastic vial. CRITICAL FROZEN.
Alternate Specimen	Serum: Red-top
Reference Range	175.3-858.2 pg/mL Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.
Performed Days	Sunday-Saturday
Turnaround Time	2-5 days



Update Existing Test	
Effective Date	5/18/2020
Name	Interleukin 6
Code	INT6
Interface Order Code	3685840
Legacy Code	INT6A
Notes	Test name, minimum volume, alternate specimen, reference range and performed days changes.
Required Testing Change	es
Name	Interleukin 6, Serum
Specimen Required	Draw blood in a SST. Centrifuge, Separate serum from cells within 2 hours and send 1.0 mL serum (0.4 mL minimum) frozen in a screw-capped plastic vial. CRITICAL FROZEN.
Alternate Specimen	Serum: Red-top
Reference Range	≤2.0 pg/mL Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.
Performed Days	Sunday-Saturday

Update Existing Test	
Effective Date	5/18/2020
Name	Interleukin 8
Code	INTL8
Interface Order Code	3684605
Legacy Code	INT8ARP
Notes	Test name, minimum volume, alternate specimen, reference range and performed days change.
Required Testing Change	es
Name	Interleukin 8, Serum
Specimen Required	Draw blood in a SST. Centrifuge, separate serum from cells within 2 hours and send 1.0 mL serum (0.4 mL minimum) frozen in a screw-capped plastic vial. CRITICAL FROZEN.
Alternate Specimen	Serum: Red-top
Reference Range	≤3.0 pg/mL Cytokine levels may demonstrate diurnal variation. For longitudinal comparision, it is recommended that cytokine levels be determined at the same time of day.
Performed Days	Sunday-Saturday



Update Existing Test	
Effective Date	5/18/2020
Name	Proinsulin, Intact
Code	PRINS
Interface Order Code	3681100
Legacy Code	PROINSARP
Notes	Specimen required updated
Required Testing Change	es
Name	Proinsulin, Intact
Specimen Required	Patient Preparation: Patient must fast 12-15 hours before collection. Draw blood in a SST. Centrifuge, separate serum from cells within 2 hours and send 1.0 mL serum (0.2 mL minimum) frozen in a screw-capped plastic vial. CRITICAL FROZEN.
Methodology	Quantitative Chemiluminescent Immunoassay

Update Existing Test	
Effective Date	5/4/2020
Name	Thiopental and Metabolite Serum/Plasma
Code	THIOS
Interface Order Code	3301520
Legacy Code	THIOS
Notes	Specimen requirement updated
Required Testing Change	es
Specimen Required	Draw blood in a plain red-top tube. Centrifuge, separate serum from cells and send 2.0 mL serum (0.7 mL minimum) frozen in a screw-capped plastic vial. CRITICAL FROZEN. Send Monday through Wednesday only.
Reference Range	See report



Update Existing Test	
Effective Date	5/18/2020
Name	Tumor Necrosis Factor Alpha, S
Code	TNFA
Interface Order Code	3685260
Legacy Code	TNFARP
Notes	Test name, alternate specimen, reference range, performed days, turnaround time changes.
Required Testing Change	25
Name	Tumor Necrosis Factor - Alpha, Serum
Specimen Required	Draw blood in a SST. Centrifuge, separate serum from cells within 2 hours and send 1.0 ml serum (0.4 mL minimum) frozen in a screw-capped plastic vial.
Alternate Specimen	Serum: Red-top
Rejection Criteria	Refrigerated specimens, heat-inactivated specimens
Reference Range	≤7.2 pg/mL Cytokine levels may demonstrate diunal variations. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.
Performed Days	Sunday-Saturday
Turnaround Time	2-6 days



Inactivate Test With Rep	lacement				
Effective Date	5/26/2020				
	Inactivated Test				
Name	Apo E Geno	Apo E Genotype for Alzheimer			
Code		APOEG			
Legacy Code ¹	Α	POEALAT			
Interface Order Code	3	500437			
Notes					
	Replacement Test				
Name	Admark [®] ApoE Genotype Ar	nalysis and Interp	pretation (Sympto)		
Code		APOE			
	81401				
CPT Code(s)	ZB08V				
Notes					
Specimen Requirements					
Specimen Required	Draw blood in a lavender EDTA tube. Send 10.0 mL whole bood (6.0 mL minimum) at room temperature.				
Rejection Criteria	Samples from patients less than 18 years old				
Stability	Room temperature: 10 days; Refrigerated: 10 days; Frozen: 90 days				
Performing Information					
Methodology	Restriction Fragment	Length Polymorp	hism (RFLP)		
Reference Range		ee report			
Performed Days	Varies				
Turnaround Time	10-16 days				
Performing Laboratory	C	uest SJC			
Interface Information					
Legacy Code ¹		APOE			
Interface Order Code		400253			
Result Code	Name	LOINC Code	AOE/Prompt ²		
3400254	Interpretation	50398-7	No		
3400255	Technical Results	42315-2	No		
3400256	Comments	77202-0	No		
3400258	Methods	49549-9	No		
3400257	References	75608-0	No		



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

		Referral Te	esting d: 04/22/2020	0 18:10	Received	: 04/22/2020	18:10
Test Name		Result	Flag	Ref-Ranges		<u>Units</u>	Site
ADmark Apo Interpretation	oE Genotype Analysis a	and Interpretatic See Note	on (Sympt	:o)			QCRL
This Technical Results		See Note					QCRL
 Inte	erpretive Result Table						
TESI TECH	ERPRETIVE RESULT: Negativ F: APOE HNICAL RESULT: Alleles: 2 NICAL RELEVANCE: See Limi	e and 3					
Comments		See Note					QCRL
	ments: While this analysi ociated with AD, a diagno		-				
is r (1,2 indi	nical limitations: The fr reported to occur in 40-5 2). This ApoE analysis is ividuals. Results cannot ividuals and should not b	0% of individuals only appropriate be interpreted for	s with Alz e for symp or asympto:	heimer's d tomatic matic	-		
disc ofte disc judg stag inca	Aground information: Alzh order and is the most com en the initial presenting ease progresses, addition gment and language. Psych ges of the disease, physi apacitation. Diagnosis re dings of amyloid plaques	mon cause of deme sign in affected al deficits devel iatric changes ma cal functioning : lies on the clin:	entia. Mem d individu lop includ ay also oc is impacte ical pictu	ory failur als. As th ing those cur. In th d which le re as well	e is e in e late ads to as		
Ther and late afte Alte year	te are different types of the presence of family h e-onset AD (LOAD) is char er 60 years old and lacki ernatively, a smaller por cs old with a strong fami (EOAD) (1) .	istory. The more acterized with syng a clear mode of tion of AD cases	common 's ymptoms us of transmi have an o	poradic' ually star ssion. nset prior	ting to 60		
isof cyst	ApoE gene has been assoc forms of ApoE, E2, E3 and teine or arginine residue E4 allele is considered	E4, that are dia at positions 13	fferentiat 12 and 158	ed by eith . Specific	er ally,		

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

Referral Testing Collected: 04/22/2020 18:10 Received: 04/22/2020 Test Name Result Elag Ref-Ranges Units acid differences impact binding capabilities of ApoE protein with other cellular products including amyloid-beta peptides. An accumulation of amyloid-beta is observed in the brains of individuals with Ab who carry the E4 allele (1). Although this allele appears to increase an individual's risk of AD, it is considered to be a reduced penetrant allele because it is not required to cause disease and it cannot predict one's risk to develop AD (3). APOE gene information: MIM ID: +107741; Chromosome Location: 19q13.32 Phenotype information: MIM ID: +104310 for Alzheimer's disease Methods See Note ApoE genotyping was performed by restriction endonuclease digestion of FCR amplified genomic DNA. Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. See Note 1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 25311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 2358530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or a					
Test Name Result Find Ref-Ranges Units acid differences impact binding capabilities of ApoE protein with other cellular products including amyloid-beta peptides. An accumulation of amyloid-beta is observed in the brains of individuals with AD who carry the E4 allele (1). Although this allele appears to increase an individual's risk of AD, it is considered to be a reduced penetrant allele because it is not required to cause disease and it cannot predict one's risk to develop AD (3). APOE gene information: MIM ID: +107741; Chromosome Location: 19q13.32 Phenotype information: MIM ID: +104310 for Alzheimer's disease Methods See Note ApoE genotyping was performed by restriction endonuclease digestion of PCR amplified genomic DNA. Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. References See Note 1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 23311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA				Referral Testing	
<pre>acid differences impact binding capabilities of ApoE protein with other cellular products including amyloid-beta peptides. An accumulation of amyloid-beta is observed in the brains of individuals with AD who carry the E4 allele (1). Although this allele appears to increase an individual's risk of AD, it is considered to be a reduced penetrant allele because it is not required to cause disease and it cannot predict one's risk to develop AD (3). APOE gene information: MIM ID: +107741; Chromosome Location: 19q13.32 Phenotype information: MIM ID: +107741; Chromosome Location: 19q13.32 Phenotype information: MIM ID: +10741; Chromosome Location of PCR amplified genomic DNA. Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. References See Note 1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. Chouraki, V, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA</pre>	18:10	1: 04/22/2020	18:10 Received	Collected: 04/22/2020	
PCR amplified genomic DNA. Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. References See Note 1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 25311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA	<u>Site</u>	<u>Units</u>	otein with s. An of individuals ele appears to to be a reduced sease and it ation: 19q13.32	acid differences impact binding capabilities of ApoE pr other cellular products including amyloid-beta peptides accumulation of amyloid-beta is observed in the brains with AD who carry the E4 allele (1). Although this alle increase an individual's risk of AD, it is considered t penetrant allele because it is not required to cause di cannot predict one's risk to develop AD (3). APOE gene information: MIM ID: +107741; Chromosome Loca Phenotype information: MIM ID: #104310 for Alzheimer's	
<pre>negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. References See Note 1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 25311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA</pre>			se digestion of.		
ReferencesSee Note1. Liu, CC, et al. (2013) Nat Rev Neurol 9: 106-18. (PMID: 23296339) 2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 25311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530)This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA			preted in the	negative results may occur. All results should be inter context of clinical findings, relevant history, and oth	
2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PMID: 25311924) 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-101. (PMID: 23583530) This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA	QCRI				
have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA			MID: 25311924)	2. Chouraki, V, et al. (2014) Adv Genet 87: 245-94. (PM 3. Roberts, JS, et al. (2013) Prog Neurobiol 110: 89-10	
			been cleared or assay has been	have been determined by Athena Diagnostics. It has not approved by the U.S. Food and Drug Administration. This validated pursuant to the CLIA regulations and is used	
license holder, Athena Diagnostics (CLIA# 22D0069726))., Ph.D., CLIA	Laboratory oversight provided by Vivekananda Datta, M.D license holder, Athena Diagnostics (CLIA# 22D0069726)	
Testing performed at: Athena Diagnostics 200 Forest Street Marlborough, MA 01752			.752		
Test Performed at: Athena Diagnostics, Inc. 200 Forest Street, 2nd Floor Marlborough, MA 01752 V Datta MD, PhD Performi	ng Site:	Deform		Athena Diagnostics, Inc. 200 Forest Street, 2nd Floor	
QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA	- ·		ISTRANO 33608 Ortega Highway	QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAF	

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

Ordered By: CLIENT CLIENT WX0000000001595 William G. Finn, M.D. - Medical Director Form: MM RL1 PAGE 2 OF 2



Inactivate Test With Rep	lacement			
Effective Date	5/4/2020			
	Inactivated Test			
Name	SARS-CoV-2 RNA, Qu		ne RT-PCR	
Code		COV19		
Legacy Code ¹		COV19		
Interface Order Code	3	400262		
Notes				
	Replacement Test			
Name	SARS-CoV-2 RNA (CO		tive NAAT	
Code		COVLR		
CPT Code(s)	87635			
Notes	This code should be used for lower repiratory specimens. Quest has created a new code for SARS-CoV2 RNA testing. All Nasopharyngeal specimens should continue to be ordered as COVWD for testing at Warde Medical Laboratory.			
Specimen Requirements				
Specimen Required	Please send 0.85 bronchoalveolar lavage/wash frozen in a screw-capped plastic container. Please send each specimen in a separate plastic bag.			
Alternate Specimen	Nasopharyngeal aspirate/wash, tracheal aspirate, or sputum			
Rejection Criteria	Amies liquid or gel transport used for bacterial cultures.			
Stability	Room temperature: 5 days; Refrigerated: 5 days; Frozen: Acceptable			
Performing Information				
Methodology	Nucleic Acid Amplification Test (NAAT), includes PCR or TMA			
Reference Range	Not detected			
Performed Days	Sunday - Saturday			
Turnaround Time	2 - 3 days (may be impacted by high volume)			
Performing Laboratory	Quest SJC			
Interface Information				
Legacy Code ¹	COVLR			
Interface Order Code	3400259			
Result Code	Name	LOINC Code	AOE/Prompt ²	
3400259	SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	94500-6	No	



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

		Referral Testi	-				
		Collected: 04	/22/2020) 18:40	Received:	04/22/2020	18:40
est Name		Result	Flag	Ref-Ranges	<u>i l</u>	<u>Jnits</u>	<u>Site</u>
SARS-CoV-2 RNA ((NAAT	COVID-19), Qualitative	DETECTED	AB				QCR
result SARS-Co and the presume health additio	cted result is considere for COVID-19. This indi DV-2 (formerly 2019-nCoV e patient is infected wi ed to be contagious. If authority, specimen wil onal testing. NCE RANGE: NOT DETECTED	cates that RNA fro) was detected, th the virus and requested by publi l be sent for					
Quest I of samp media s patient samples being t from sp manufac media, not yet should potent: as add:	the current public heal Diagnostics is receiving oles from a wide variety for COVID-19 testing. In the during this public he from appropriate clini tested. Negative test re becimens received in non trured viral collection or in media and sample that authorized by FDA for be cautiously evaluated ally subjected to extra tional clinical monitor	a high volume of swabs and order to serve alth crisis, cal sources are sults derived -commercially and transport collection kits COVID-19 testing and the patient precautions such ing, including					
an Emer	est has been authorized rgency Use Authorization norized laboratories.	-					
Methodo	ology: Real-Time RT-PCR	L.					
provide labelin	review the 'Fact Sheets ers, and patients and th ng available on the Ques estDiagnostics.com/Covid	e FDA authorized t website:					
Quest I 33608 (erformed at: Diagnostics Infectious D Drtega Highway An Capistrano, CA 92675		erman 1	ИD			
						Perform	ning Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



Inactivate Test With Rep	lacement				
Effective Date	5/18/2020				
	Inactivated Test				
Name	Phosphatidylethanol (PEth)				
Code		PETH			
Legacy Code ¹		PETH			
Interface Order Code	3	623100			
Notes					
	Replacement Test				
Name	Phosphatidyletha	nol (PEth), Whole	e Blood		
Code		PETHB			
CPT Code(s)	80321 (G0480)				
Notes					
Specimen Requirements					
Specimen Required	Draw blood in a lavender EDTA tube. Send 1.0 mL whole bood (0.5 mL minimum) refrigerated.				
Alternate Specimen	Blood: Green lithium heparin, gray potassium oxalate				
Rejection Criteria	SST, plain red top, light blue sodium citrate, yellow (ACD or SPS)				
Stability	Room temperature: Unacceptable; Refrigerated: 2 weeks; Frozen: 1 month				
Performing Information					
Methodology	Quantitative Liquid Chromatography - Tandem Mass Spectrometry				
Reference Range	<10 ng/mL				
Performed Days	Sunday-Saturday				
Turnaround Time	3-6 days				
Performing Laboratory	ARUP Reference Laboratory				
Interface Information					
Legacy Code ¹	PETHB				
Interface Order Code	3	600171			
Result Code	Name	LOINC Code	AOE/Prompt ²		
3600172	PEth 16:0/18.1 (POPEth)	74661-0	No		
3600173	PEth 16:0/18.2 (PLPEth) Not Available No				



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

	Colle	cted: 04/22/2020	18:42 Rec	eived: 04/22/2020	18:42
est Name	<u>Result</u>	Flag	Ref-Ranges	<u>Units</u>	Site
Phosphatidylethanol (PEth), Wi	nole Blood				
Eth 16:0/18.1 (POPEth)	<10			ng/mL	ARR
INTERPRETIVE INFORMATION	:Phosphatidylethan Blood	ol (PEth), Wh	nole	-	
Phosphatidylethanol (PEt homologues	h)	erpretation			
PEth 16:0/18.1 (POPEth) Less than 10 ng/mL Less than 20 ng/mL 20 - 200 ng/mL Greater than 200 ng/mL	Abstinence consumptio Moderate a	or light alc n lcohol consum hol consumpti	nption		
PEth 16:0/18.2 (PLPEth). well		-	ot		
(Reference: W. Ulwelling	establishe and K Smith 2018		Sci)		
Phosphatidylethanol (PEt formed in the presence o phosphatidylcholine. PEt biomarker. The predomina 16:0/18:1 (POPEth) and P account for 37-46% and 2 respectively. PEth is in membrane of red blood ce 4 - 10 days and a window However, the window of d who chronically or exces of quantification is 10 may be helpful in monito PEth results should be i patients clinical and be advanced liver disease m concentrations (Nguyen V Experimental Research).	f ethanol, phospho h is known to be a nt PEth homologues Eth 16:0/18:2 (PLP 6-28% of the total corporated into th lls and has a gene of detection of 2 etection is longer sively consume alc ng/mL. Serial moni ring alcohol absti nterpreted in the havioral history. ay have falsely el	lipase D and direct alcoh are PEth Eth), which PEth homolog e phospholipi ral half-life -4 weeks. in individua ohol. The lim toring of PEt nence over ti context of th Patients wit evated PEth	gues, id als nit th ime. he th		

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS Performed By: ARUP Laboratory 500 Chipeta Way

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



EXAMPLE, REPORT WX0000003039 M 12/05/1988 31 Y

	Referral Te	sting				
	Collected	: 04/22/2020) 18:42	Received:	04/22/2020	18:42
<u>Test Name</u> Salt Lake City, UT 84108	<u>Result</u>	<u>Flag</u>	Ref-Ranges	<u> </u>	<u>Jnits</u>	<u>Site</u>
PEth 16:0/18.2 (PLPEth)	<10			n	ıg/mL	ARRL
Performed By: ARUP Laboratory 500 Chipeta Way Salt Lake City, UT 84108 Performed by ARUP Laboratorie 500 Chipeta Way, SLC,UT 84108 www.aruplab.com, Julio Delgad	es, 8 800-522-2787	ector				
Performing Site: ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221						

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



Inactivate Test Withou	ut Replacement
Effective Date	4/17/2020
Name	Chymopapain IgE
Code	RC209
Legacy Code	RARC209
Interface Code	3062380
Notes	